Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulonivirine (MK-8507) in HIV-1 Infected Patients
NCT02174159Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ulonivirine in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Merck & Co. Primary endpoints: Change from Baseline in Plasma HIV-1 RNA at 168 hours and Number of Participants with One or More Adverse Experiences up to 21 days. Started Sep 2014; status: completed.
02
Drugs
ulonivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02174159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174159.